

## Manuscript submitted to Dove Medical Press

1 message

**Mrs Whimp** <deidrewhimp@dovepress.com>  
Reply-To: Mrs Whimp <deidrewhimp@dovepress.com>  
To: Dr Bahar <akbarbahar@unhas.ac.id>

Mon, Jan 9, 2023 at 12:22 PM

Dear Dr Bahar,

Thank you for your recent submission to Infection and Drug Resistance, titled "Knowledge, Attitudes, and Perceptions of Tuberculosis in Indonesia: A multi-center cross-sectional study" which has been received.

You uploaded the following files with this submission:

404171-ms.docx  
404171-figure-4-response-patterns-to-questions-about-the-perception-toward-tb-.jpg  
404171-figure-3-response-patterns-to-questions-about-the-attitude-toward-tb.jpg  
404171-figure-2-response-patterns-to-questions-about-the-knowledge-of-tb.jpg  
404171-figure-1-data-collection-site-of-the-cross-sectional-study.jpg  
404171-table-5-independent-determinants-of-tb-knowledge-attitude-and-perception-score.docx  
404171-table-4-potential-determinants-of-tb-perception-score.docx  
404171-table-3-potential-determinants-of-tb-attitude-score.docx  
404171-table-2-potential-determinants-of-tb-knowledge-score.docx  
404171-table-1-sociodemographic-characteristics-of-the-study-participants.docx  
404171-cover-letter.docx  
404171-graphical-abstracts-kap-edit.png

### CONFLICT OF INTEREST DISCLOSURE

Please now complete the disclosure form by clicking on the following link:

[https://www.dovepress.com/icmje\\_coi.php?submission\\_id=404171&author\\_id=1841814&t=tfknlvsggzadzpnq](https://www.dovepress.com/icmje_coi.php?submission_id=404171&author_id=1841814&t=tfknlvsggzadzpnq)

The purpose of this form is to provide the Editor-in-Chief of Infection and Drug Resistance with important information about your possible conflicts of interests. The composition of this form follows that of the International Committee of Medical Journal Editors (ICMJE) standard and further demonstrates our commitment to the highest ethical and professional standards.

The form is designed to be completed and stored electronically. When the manuscript has been sent for peer review each author will receive an individual email like this and should submit a separate form. Each author is responsible for the accuracy and completeness of the submitted information.

What happens next:

=====

Your submission will be given an initial review to ensure its suitability for Infection and Drug Resistance. Once that has been completed, peer review will commence, and we will be in contact again when that has been completed.

If your paper is accepted for publication you will need to pay an article publishing charge of USD 1418 (plus VAT if applicable). This discount has been provided as part of our waiver program based on the country of the contact persons primary affiliation. Provision of this waiver is subject to the details provided in this submission being correct.

What to do if you have questions:

=====

At any time throughout the submission process you are welcome to contact the Editorial Team should you have any questions about your submission. The status of your submission can also be tracked through DoveCentral. You will automatically be notified of changes in the status of your submission.

A reminder of manuscript submission terms and conditions:

=====

Please note that your submission has been received on the basis of your agreement with the terms and conditions which you were asked to consent to during the submission process. These are outlined again below and are available in full on the website ([https://www.dovepress.com/author\\_guidelines.php?content\\_id=771](https://www.dovepress.com/author_guidelines.php?content_id=771)):

- The submission is in compliance with the author guidelines and any applicable journal-specific guidelines; and,

- My co-authors (if any) have authorized me to submit our manuscript; and,
- I am not in a conflict of interest; and,
- I have read and understood the copyright terms; and,
- I have read and understood the article publishing charge terms and I understand that unless I have previously applied for a waiver I will be required to pay an article publishing charge before my paper can progress any further if my paper is accepted for publication. Note that article publishing charge invoiced to EU countries are subject to 20% VAT; and,
- The manuscript I am submitting is not currently under consideration for publication in another journal, nor has it been published in another journal; and,
- I have clearance to reproduce any copyrighted material; and,
- Nothing in the submission is unlawful, libelous or would constitute a breach of contract or confidence or commitment to secrecy; and,
- I absolve Dove Medical Press Ltd from all legal liability arising from my submission; and,
- I have taken due care to ensure integrity of the submission and according to currently accepted scientific knowledge all statements in it purporting to be facts are true.

Some institutions have an open access fund available to their researchers, which can help to pay for the publication processing fee. We encourage you to contact your institution library to enquire if this is available to you.

#### Changes to authorship

=====

Dove does not permit the changing/adding/deleting of authors after submission of the paper. We support the GPP3 guidelines that indicate addition or removal of an author should only happen in rare cases, such as the work changing substantially in response to the reviewer or Editor's comments.

Many thanks for your submission.

Yours sincerely

Mrs Whimp  
Editorial Department  
Dove Medical Press

[www.dovepress.com](http://www.dovepress.com) - open access to scientific and medical research

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC  
(ID: 404171)

---

## Form for Disclosure of Potential Conflicts of Interest [ID 404171] Completed

1 message

---

**Mrs Whimp** <deidrewhimp@dovepress.com>  
Reply-To: Mrs Whimp <deidrewhimp@dovepress.com>  
To: Dr Bahar <akbarbahar@unhas.ac.id>

Mon, Jan 9, 2023 at 7:33 PM

Dear Dr Bahar

Regarding your manuscript 'Knowledge, Attitudes, and Perceptions of Tuberculosis in Indonesia: A multi-center cross-sectional study'

I confirm we have received your completed Conflict of Interest disclosure.

If I can be of further assistance, please do not hesitate to contact me.

Kind regards  
Mrs Whimp

Editorial Department  
Dove Medical Press  
[www.dovepress.com](http://www.dovepress.com) - open access to scientific and medical research  
Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC  
[ID: 404171]

---

## Manuscript submitted to Infection and Drug Resistance [ID 404171]

3 messages

---

**Dr Hanson-Manful** <paulinahanson-manful@dovepress.com>  
Reply-To: Dr Hanson-Manful <paulinahanson-manful@dovepress.com>  
To: Dr Bahar <akbarbahar@unhas.ac.id>

Mon, Jan 16, 2023 at 5:46 AM

Dear Dr Bahar

Thank you for your submission to Infection and Drug Resistance titled 'Knowledge, Attitudes, and Perceptions of Tuberculosis in Indonesia: A multi-center cross-sectional study'.

We have identified that your paper involves research on humans (individuals, samples or data). Although you have provided an ethics statement, some elements are missing/inaccurate and these need to be addressed. We note that your manuscript appears to include participants who are 17years of age:

- please confirm if all participants were above the age of consent in your country in the manuscript
- alternatively, if any minors were involved, please confirm in your manuscript if consent was provided from the legal guardian

We have temporarily withdrawn your submission to allow you to address these issues. Please amend your manuscript as necessary, and upload the revised file using the following link to have your submission reinstated:

[https://www.dovepress.com/upload\\_files\\_new.php?submission\\_id=404171&l=mqFVaVD19L9SUCwcMRi8xfj81841814](https://www.dovepress.com/upload_files_new.php?submission_id=404171&l=mqFVaVD19L9SUCwcMRi8xfj81841814)

For more information on Dove Medical Press' guidelines for ethics, please see our webpage: [https://www.dovepress.com/editorial\\_policies.php?content\\_id=3525](https://www.dovepress.com/editorial_policies.php?content_id=3525)

Kind regards

Dr Hanson-Manful  
Consulting Editor  
Dove Medical Press  
Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC  
(ID 404171)

---

**Muh. Akbar Bahar** <akbarbahar@unhas.ac.id>  
To: Ikhwan Yuda Kusuma <ikhwanyudakusuma@uhs.ac.id>, Silma Kaaffah <silmakaaffah92@gmail.com>

Mon, Jan 16, 2023 at 10:49 PM

Sekedar infromasi, tapi saya sudah coba revisi dan resubmit lagi.

Kind regards,

Muh. Akbar Bahar, Ph.D, Apt  
Faculty of Pharmacy, Universitas Hasanuddin  
Makassar, South Sulawesi, Indonesia

[Quoted text hidden]

---

**Silma Kaaffah** <silmakaaffah92@gmail.com>  
To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>

Mon, Jan 16, 2023 at 10:54 PM

Baik pak, terimakasih informasinya

[Quoted text hidden]

## Submission to Infection and Drug Resistance [Sub ID 404171]

1 message

**Ms Tozer** <anna.tozer@dovepress.com>  
Reply-To: Ms Tozer <anna.tozer@dovepress.com>  
To: Dr Bahar <akbarbahar@unhas.ac.id>

Tue, Jan 17, 2023 at 1:29 PM

Dear Dr Bahar

Your recent submission to Infection and Drug Resistance titled "Knowledge, Attitudes, and Perceptions of Tuberculosis in Indonesia: A multi-center cross-sectional study" has now completed the initial editorial checks and has been sent for peer review.

Most of the submission process is automated and you can follow the progress of your manuscript by logging into your Dove account. For an explanation of the different status indicators please click on the following link:

<https://www.dovepress.com/author-guidelines/submission-status>

Our publication policy specifies that every manuscript must have a minimum of two sets of peer review comments in order that the editorial decision-maker can reach a conclusion on the manuscript. When we have the required number of peer review reports returned your manuscript will be sent for first editorial decision. Once we have been advised of the Editor-in-Chief's decision you will be notified by email and provided with the peer-reviewers comments.

Please now complete the disclosure form by clicking on the following link:

[https://www.dovepress.com/icmje\\_coi.php?submission\\_id=404171&author\\_id=1841814&t=zuppmocbhldaeqng](https://www.dovepress.com/icmje_coi.php?submission_id=404171&author_id=1841814&t=zuppmocbhldaeqng)

Please note, due to the confidential nature of our correspondence the Conflict of Interest form must be completed by each author from their author login, each of the co-authors will receive an individualised link by email. We cannot accept any form completed by or returned from any author other than the intended recipient.

The purpose of this form is to provide the Editor-in-Chief of Infection and Drug Resistance with important information about your possible conflicts of interests. The composition of this form follows that of the International Committee of Medical Journal Editors (ICMJE) standard and further demonstrates our commitment to the highest ethical and professional standards.

The form is designed to be completed and stored electronically. Each author will receive an individual email like this and should submit a separate form. Each author is responsible for the accuracy and completeness of the submitted information.

Click on the following link to provide your full name in your native language:

[https://www.dovepress.com/update\\_user.php?t=qxpvmxcxrbnktfde](https://www.dovepress.com/update_user.php?t=qxpvmxcxrbnktfde)

ORCID ID

Please click on the link below to add your ORCID ID:

[https://www.dovepress.com/update\\_user.php?t=qxpvmxcxrbnktfde](https://www.dovepress.com/update_user.php?t=qxpvmxcxrbnktfde)

Don't have an ORCID ID yet?

No problem. You can use the link above to register for one also.

Don't know what an ORCID ID is?

ORCID provides a persistent digital identifier that distinguishes you from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between you and your professional activities ensuring that your work is recognized.

If you have any queries regarding this manuscript please let me know.

Kind regards

Ms Tozer

Infection and Drug Resistance

Dove Medical Press

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC



---

## Manuscript Update Infection and Drug Resistance [Sub ID 404171]

1 message

---

**Ms Tozer** <anna.tozer@dovepress.com>

Thu, Jan 19, 2023 at 9:26 PM

Reply-To: Ms Tozer <anna.tozer@dovepress.com>

To: Dr Bahar <akbarbahar@unhas.ac.id>

Dear Dr Bahar

Your manuscript 'Knowledge, Attitudes, and Perceptions of Tuberculosis in Indonesia: A multi-center cross-sectional study' submitted to Infection and Drug Resistance has moved to status 'First Report Returned'. We are waiting for the final review comments to be returned.

When we have the required number of peer review reports returned your manuscript will be sent for first editorial decision. Once we have been advised of the Editor-in-Chief's decision the nominated contact person will be notified by email and provided with the peer-reviewers comments.

If I can be of further assistance, please do not hesitate to contact me.

Kind regards

Ms Tozer

Infection and Drug Resistance

Dove Medical Press

[www.dovepress.com](http://www.dovepress.com) - open access to scientific and medical research

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC

(ID 404171)

---

## Your manuscript has been sent to the Editor-in-Chief [ID 404171]

1 message

---

**Soumya Khanapur** <soumyakhanapur@dovepress.com>  
Reply-To: Soumya Khanapur <soumyakhanapur@dovepress.com>  
To: akbarbahar@unhas.ac.id

Wed, Feb 1, 2023 at 3:46 AM

Dear Dr Bahar

Journal Name: Infection and Drug Resistance  
Title: Knowledge, Attitudes, and Perceptions of Tuberculosis in Indonesia: A multi-center cross-sectional study  
ID: 404171  
Author: Dr Bahar

We are happy to advise that your manuscript and comments from the peer-reviewers have been delivered to our Editor-in-Chief to review and comment. We will be in touch shortly with the outcome.

Please note that the decision of the Editor-in-Chief whether to accept or reject any paper is full and final.

Please do not hesitate to contact us if you have any questions.

Don't forget to register for email alerts to this journal by clicking here:  
[https://www.dovepress.com/quick\\_signup.php?journal\\_id=28&l=mqFVaVD19L9SUCwcMRi8xfj81841814](https://www.dovepress.com/quick_signup.php?journal_id=28&l=mqFVaVD19L9SUCwcMRi8xfj81841814)

Sincerely,

Soumya Khanapur  
Editorial Department  
Dove Medical Press Ltd  
Live Chat: [https://www.dovepress.com/live\\_help.t](https://www.dovepress.com/live_help.t)  
[www.dovepress.com](https://www.dovepress.com) - open access to scientific and medical research  
Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC

---

## Dove Medical Press – Confirmation of Revision Period

1 message

---

**Soumya Khanapur** <soumyakhanapur@dovepress.com>  
Reply-To: Soumya Khanapur <soumyakhanapur@dovepress.com>  
To: Dr Bahar <akbarbahar@unhas.ac.id>

Wed, Feb 8, 2023 at 12:49 PM

Dear Dr Bahar

Titled: Knowledge, Attitudes, and Perceptions of Tuberculosis in Indonesia: A multi-center cross-sectional study  
Submission ID: 404171

Thank you for confirming your intention to submit a revised manuscript for Infection and Drug Resistance. I have noted a due date of 22 Feb 2023 in our system. If you require further time, please let us know as soon as possible. We look forward to receiving your revised manuscript.

When submitting your revised manuscript, please include a point-by-point response letter. This letter must contain all comments made by the reviewers, the Editor and the editorial staff, and your responses to these comments. The response letter assists the Editor in their final decision.

Dove Medical Press does not generally permit changes to the author list of a submitted manuscript. As per our Authorship Policies ([https://www.dovepress.com/editorial\\_policies.php?content\\_id=3521](https://www.dovepress.com/editorial_policies.php?content_id=3521)) we support the GPP3 guidelines which indicate that the addition or removal of an author should only occur in rare cases, such as the work undergoing substantial revisions in response to reviewer or Editor comments.

Please use the following link to submit your revised manuscript, response letter and any additional revised or requested files.  
[https://www.dovepress.com/upload\\_files\\_new.php?submission\\_id=404171&l=mqFVaVD19L9SUCwcMRi8xfj81841814](https://www.dovepress.com/upload_files_new.php?submission_id=404171&l=mqFVaVD19L9SUCwcMRi8xfj81841814)

### VIDEO ABSTRACT

We would also like to invite you to submit a short video abstract, which will be published with your paper. This is an initiative that encourages videos to be presented by the author(s). The video should be of 1-3 minutes duration and give an overview of their paper, so readers can get an idea of the content and motivation behind the paper.

If you are able to prepare a video abstract for this paper please ensure this is completed and submitted at the same time as your revised manuscript, as we will be unable to accept a video abstract at a later stage in the process. In the meantime the guidelines and an example video abstract are available here:

[https://www.dovepress.com/author\\_guidelines.php?content\\_id=3195](https://www.dovepress.com/author_guidelines.php?content_id=3195)

Kind regards

Soumya Khanapur  
[soumyakhanapur@dovepress.com](mailto:soumyakhanapur@dovepress.com)

Dove Medical Press

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC

[ID 404171]

## Manuscript submitted to Dove Medical Press - Response Required

9 messages

**Soumya Khanapur** <soumyakhanapur@dovepress.com>  
Reply-To: Soumya Khanapur <soumyakhanapur@dovepress.com>  
To: Dr Bahar <akbarbahar@unhas.ac.id>

Wed, Feb 8, 2023 at 11:18 AM

Dear Dr Bahar ,

Thank you for your manuscript submission to Infection and Drug Resistance. On behalf of the Editor, I would like to inform you that your submitted manuscript "Knowledge, Attitudes, and Perceptions of Tuberculosis in Indonesia: A multi-center cross-sectional study" (404171) has been peer-reviewed and may be considered for publication after the necessary revisions are completed to the Editors satisfaction.

### EDITOR/EDITORIAL/REVIEWER COMMENTS:

Please download your required editorial corrections and reviewer comments from your author interface below:

[https://www.dovepress.com/manuscript\\_revision.php?pa=reviewer\\_comment&submission\\_id=404171&l=mqFVaVD19L9SUCwcMRi8xfj81841814](https://www.dovepress.com/manuscript_revision.php?pa=reviewer_comment&submission_id=404171&l=mqFVaVD19L9SUCwcMRi8xfj81841814)

### \*IMPORTANT\*

We require you to confirm that you wish to proceed and intend to submit a revised manuscript. You can do this by confirming your intention to revise by using the calendar supplied on your author dashboard, or you can reply to this email.

[https://www.dovepress.com/manuscript\\_revision.php?submission\\_id=404171&l=mqFVaVD19L9SUCwcMRi8xfj81841814](https://www.dovepress.com/manuscript_revision.php?submission_id=404171&l=mqFVaVD19L9SUCwcMRi8xfj81841814)

Once you confirm your intention to revise, we will send a confirmation email that contains a link to submit your revised files.

Please note the standard revision period is 21 days. If, after you have considered the reviewer comments, you decide that you require longer than 21 days to revise and resubmit, please let us know immediately.

If you have any further queries or concerns, please do not hesitate to contact us.

Kind Regards,

Soumya Khanapur

On behalf of Professor Suresh Antony

Editorial Department

Dove Medical Press

[www.dovepress.com](http://www.dovepress.com) - open access to scientific and medical research

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC

**Muh. Akbar Bahar** <akbarbahar@unhas.ac.id>

Wed, Feb 8, 2023 at 11:49 AM

To: Ikhwan Yuda Kusuma <ikhwanyudakusuma@uhb.ac.id>, Silma Kaaffah <silmakaaffah92@gmail.com>

Dear all,

Alhamdulillah diberi kesempatan direvisi. Saya baca komentar tiga reviewer bagus-bagus dan hanya sedikit yg perlu direvisi. Mohon bantuan disiapkan perbaikan dan rebuttal letternya. Nanti setelah itu, saya cek. terima kasih. Kira-kira berapa lama waktu revisi yang diperlukan? soalnya saya harus infokan tanggal ke editor.

Kind regards,

Muh. Akbar Bahar, Ph.D, Apt

Faculty of Pharmacy, Universitas Hasanuddin

Makassar, South Sulawesi, Indonesia

[Quoted text hidden]

**Muh. Akbar Bahar** <akbarbahar@unhas.ac.id>

Wed, Feb 8, 2023 at 11:51 AM

To: Ikhwan Yuda Kusuma <ikhwanyudakusuma@uhb.ac.id>, Silma Kaaffah <silmakaaffah92@gmail.com>

In case tidka bisa di download.

Kind regards,

## Infection and Drug Resistance – Revised Manuscript Corrections

4 messages

**Soumya Khanapur** <soumyakhanapur@dovepress.com>  
Reply-To: Soumya Khanapur <soumyakhanapur@dovepress.com>  
To: Dr Bahar <akbarbahar@unhas.ac.id>

Wed, Mar 8, 2023 at 5:27 AM

Dear Dr Bahar

I am contacting you regarding your revised manuscript which was recently resubmitted titled 'Knowledge, Attitudes, and Perceptions of Tuberculosis in Indonesia: A multi-center cross-sectional study' (ID: 404171)

Upon beginning to process your revised manuscript, we have noticed some issues that prevent us from forwarding your submission to the Editor for final editorial review. Please use the link below to find a list of your files which need further correction. All the required corrections can be found in the included manuscript file as comments, and you will need to perform and respond to each of the requested corrections.

[https://www.dovepress.com/upload\\_files\\_new.php?submission\\_id=404171&l=mqFVaVD19L9SUCwcMRi8xfj81841814](https://www.dovepress.com/upload_files_new.php?submission_id=404171&l=mqFVaVD19L9SUCwcMRi8xfj81841814)

We may have also made minor changes to the word document file in accordance with our house style. These changes will be clearly explained and tagged within the manuscript. Using the comment function, please confirm these changes are acceptable by replying to our comments with "accept". Please ensure this is completed in the same word document file(s) that has been downloaded. You must then reupload the word document file(s) after making any requested changes, in conjunction with any other required files through the 'Upload corrected files' section at the bottom of the page above.

Please perform or respond to each of the requested corrections, then upload the corrected files through the 'Upload corrected files' section at the bottom of the page above.

Once we receive the corrected files, we will continue processing your submission, and provided we do not encounter any further issues which need correcting, will notify you once it has been sent to the Editor for final decision.

Please don't hesitate to contact me if you have queries about any of the requested corrections.

Regards,

Soumya Khanapur  
Revised Manuscript Co-ordinator  
Dove Medical Press  
[www.dovepress.com](http://www.dovepress.com) - open access to scientific and medical research  
Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC

**Muh. Akbar Bahar** <akbarbahar@unhas.ac.id>  
To: Silma Kaaffah <silmakaaffah92@gmail.com>, Ikhwan Yuda Kusuma <ikhwanyudakusuma@uhb.ac.id>


Wed, Mar 8, 2023 at 3:19 PM

Ada diminta perbaikan lagi, tapi kalau saya cek cuma raphical abstract. Mungkin bisa dibantu cek bagian mana lagi yg mereka ubah.

Kind regards,

Muh. Akbar Bahar, Ph.D, Apt  
Faculty of Pharmacy, Universitas Hasanuddin  
Makassar, South Sulawesi, Indonesia

[Quoted text hidden]

 **08\_Mar\_2023\_404171\_Revised\_Manuscript\_for\_corrections\_-\_v2.docx**  
117K

**Silma Kaaffah** <silmakaaffah92@gmail.com>  
To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>  
Cc: Ikhwan Yuda Kusuma <ikhwanyudakusuma@uhb.ac.id>

Wed, Mar 8, 2023 at 3:39 PM

---

## Your manuscript has been sent to the Editor-in-Chief

1 message

---

**soumyakhanapur@dovepress.com** <soumyakhanapur@dovepress.com>

Mon, Mar 20, 2023 at 10:03 AM

Reply-To: soumyakhanapur@dovepress.com

To: Dr Bahar <akbarbahar@unhas.ac.id>

Dear Dr Bahar

Journal Name: Infection and Drug Resistance

Title: Knowledge, Attitudes, and Perceptions of Tuberculosis in Indonesia: A multi-center cross-sectional study

ID: 404171

Author: Dr Bahar

We confirm receipt of your manuscript, which has now been delivered to our Editor-in-Chief to review and make their final decision. We will be in touch shortly with the outcome.

Please note that the decision of the Editor-in-Chief whether to accept or reject any paper is final and final.

For a guide to submission status indicators please click on the following link:

[https://www.dovepress.com/author\\_guidelines.php?folder\\_id=206](https://www.dovepress.com/author_guidelines.php?folder_id=206)

Please do not hesitate to contact us if you have any questions.

Sincerely,

Soumya Khanapur

Editorial Department

Dove Medical Press Ltd

Live Chat: [https://www.dovepress.com/live\\_help.t](https://www.dovepress.com/live_help.t)

[www.dovepress.com](http://www.dovepress.com) - open access to scientific and medical research

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC

## Dove Medical Press: Submission accepted for publication

3 messages

**Ms Sandi Mclver** <sandi@dovepress.com>  
Reply-To: Ms Sandi Mclver <sandi@dovepress.com>  
To: Dr Bahar <akbarbahar@unhas.ac.id>

Thu, Mar 23, 2023 at 6:55 AM

Dear Dr Bahar,

I am pleased to inform you that the submission, "Knowledge, Attitudes, and Perceptions of Tuberculosis in Indonesia: A multi-center cross-sectional study", has been accepted for publication in "Infection and Drug Resistance". The article publishing charge is now payable before the paper can be progressed any further and an invoice is accessible here: [https://www.dovepress.com/invoice.php?i\\_key=nhJsAChTdq1nH5LpkUOgNGyz65027](https://www.dovepress.com/invoice.php?i_key=nhJsAChTdq1nH5LpkUOgNGyz65027)

(If you require any amendments to your invoice please reply to this email. Please note invoices cannot be amended once a payment has been made)

The above acceptance for publication is conditional upon the required copyright permissions being obtained, if applicable.

The fee can be paid by credit card (Visa, MasterCard or AMEX) or bank transfer\*. Instructions are given below, which we strongly recommend you read before organizing payment.

**Paying by credit card:**

Click on the URL given above to be taken to our secure credit card payment gateway. Because credit card payments are immediate, we recommend using this method to ensure that processing of your paper continues promptly. When processing your payment through the secure credit card system you will need to remain on the payment pages until the transaction has completed – either successful or failed. Do not close your browser during this time.

**Paying by bank transfer:**

Please forward the invoice accessible through the URL given above together with this information to your organization's accounts administrator:

**Bank transfer details:**

BNP Paribas London  
10 Harewood Avenue, London, NW1 6AA

Account name: Dove Medical Press Ltd

Account No.: 87810020 (This account is for USD transactions only)

Sort code: 40-63-84

VAT No.: GB 365 462 636

IBAN: GB70BNPA40638487810020

SWIFT BIC: BNPAGB22

CORRESPONDENT: BNPAUS3N (Intermediary Bank)

**IMPORTANT NOTES WHEN PAYING BY BANK TRANSFER:**

\* Bank transfer costs: If paying by bank transfer you must ensure that the full amount of the invoice is transferred to Dove Medical Press. Any bank fees should be at the senders expense as under-payment of your invoice will result in delays to your paper being published.

- Please instruct your accounts administrator to include your submission ID in the payment information provided when the transfer is initiated.

PLEASE NOTE: We do not accept payment by check.

**Receipts:**

If you require a receipt please let me know.

The acceptance of your paper is subject to all outstanding content-related queries being addressed to the satisfaction of the Publisher.

If you have any questions about your paper please contact us at any time, we welcome your feedback.